StockData
Cooper Companies, Inc. logo

Cooper Companies, Inc. (COO) KPIs and segments

COONasdaqOphthalmic GoodsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 16/3040% below fair value
$60.75+0.03 (+0.05%)

Close on Nov 18, 2026Market cap $11.55BP/E 20.7Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Cooper Companies · năm tài chính kết thúc ngày 31 tháng 10

Nhìn nhanh KPI của Cooper Companies: 37 chỉ số vận hành, trong đó có CooperVision — Organic Revenue Growth (YoY), Toric & Multifocal Lenses và Sphere & Other Lenses, lấy từ 184 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Cooper Companies kết thúc ngày 31 tháng 10 — Q4 FY26 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Q1 FY24
Coopervision Segment($M)2
717724695710718670646676676636622
Toric and multifocal($M)
364365351345359328319323326310297
Sphere, other($M)
353359344365360341327353349326324
CooperVision($M)
717724695710718670646
Coopersurgical Segment($M)2
349358329355342333319342327307310
Office and surgical($M)
208214202215205206199203198183191
Fertility($M)
141144127141137127120139129124119
CooperSurgical($M)
349358329355342333319
United States($M)
520548514526516515496505511479470
Europe($M)
358342326331343292288306297277277
Rest of world($M)
189192184201195181195187185
CooperVision($M)
206216210157203186184
Coopervision Segment($M)
203186184173160155
CooperSurgical($M)
41.1-22526.83.70-4.2023.720.2
Coopersurgical Segment($M)
-4.2023.720.241.321.624
CooperVision($M)
477494474436480454441
CooperSurgical($M)
235241221215212225219
CooperSurgical($M)
-8.30-9.80-8-6.50-10.5-8.70-13.8
CooperVision($M)
-60.4-76.6-94.2-91.5-86.4-69.4-75.6
CooperVision($M)
7,9157,6267,6567,6047,285
Coopervision Segment($M)
7,5127,4637,2597,2857,1727,1157,130
Coopersurgical Segment($M)
4,6714,7644,7784,8324,7174,6924,663
CooperSurgical($M)
4,5434,6164,5854,6194,832
CooperVision — Organic Revenue Growth (YoY)(%)4
0.0%4.0%3.0%3.0%2.0%7.0%6.0%8.0%10.0%11.0%7.0%
Constant Currency Revenue Growth (YoY)(%)
0.0%4.0%3.0%3.0%2.0%7.0%6.0%8.0%9.0%10.0%6.0%
Reported GAAP Revenue Growth (YoY)(%)
0.0%8.0%8.0%5.0%6.0%5.0%4.0%9.0%7.0%8.0%7.0%
Foreign Currency Impact on Growth(%)
0.0%-4.0%-5.0%-2.0%-4.0%2.0%2.0%-1.0%2.0%2.0%
Acquisitions & Divestitures Impact on Growth(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%1.0%1.0%
Toric & Multifocal Lenses — Organic Revenue Growth (YoY)(%)3
2.0%7.0%6.0%5.0%6.0%7.0%10.0%9.0%12.0%12.0%12.0%
Constant Currency Growth (YoY)(%)
2.0%7.0%6.0%5.0%6.0%7.0%10.0%9.0%12.0%12.0%12.0%
Reported Growth (YoY)(%)
1.0%11.0%10.0%7.0%10.0%6.0%7.0%9.0%10.0%11.0%14.0%
Foreign Currency Impact(%)
1.0%-4.0%-4.0%-2.0%-4.0%1.0%3.0%0.0%2.0%1.0%
Sphere & Other Lenses — Organic Revenue Growth (YoY)(%)3
-1.0%1.0%1.0%2.0%-1.0%6.0%3.0%7.0%8.0%9.0%3.0%
Constant Currency Growth (YoY)(%)
-1.0%1.0%1.0%2.0%-1.0%6.0%3.0%7.0%7.0%8.0%1.0%
Reported Growth (YoY)(%)
-2.0%5.0%5.0%3.0%3.0%5.0%1.0%8.0%5.0%5.0%1.0%
Foreign Currency Impact(%)
1.0%-4.0%-4.0%-1.0%-4.0%1.0%2.0%-1.0%2.0%3.0%
MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY)(%)
20.0%24.0%23.0%
CooperVision EMEA — Net Sales($M)4
309290282277292249247257257237238
EMEA Organic Growth (YoY)(%)
5.0%6.0%4.0%3.0%6.0%6.0%6.0%11.0%7.0%14.0%10.0%
EMEA Constant Currency Growth (YoY)(%)
5.0%6.0%4.0%3.0%6.0%6.0%6.0%11.0%7.0%13.0%8.0%
EMEA Reported Growth (YoY)(%)
6.0%17.0%15.0%8.0%14.0%5.0%3.0%14.0%6.0%13.0%11.0%
EMEA Foreign Currency Impact(%)
-1.0%-11.0%-11.0%-5.0%-8.0%1.0%3.0%-3.0%1.0%0.0%
CooperVision Americas — Net Sales($M)4
282303289285286282271271280264253
Americas Organic Growth (YoY)(%)
-2.0%7.0%6.0%5.0%3.0%8.0%8.0%6.0%13.0%10.0%6.0%
Americas Constant Currency Growth (YoY)(%)
-2.0%7.0%6.0%5.0%3.0%8.0%8.0%6.0%13.0%8.0%4.0%
Americas Reported Growth (YoY)(%)
-2.0%7.0%7.0%5.0%2.0%7.0%7.0%5.0%13.0%9.0%5.0%
Americas Foreign Currency Impact(%)
0.0%0.0%-1.0%0.0%1.0%1.0%1.0%1.0%0.0%-1.0%
CooperVision Asia Pacific — Net Sales($M)4
126131124147140139129149139135131
Asia Pacific Organic Growth (YoY)(%)
-5.0%-6.0%-4.0%0.0%-5.0%5.0%3.0%7.0%7.0%7.0%7.0%
Asia Pacific Constant Currency Growth (YoY)(%)
-5.0%-6.0%-4.0%0.0%-5.0%5.0%3.0%7.0%7.0%7.0%6.0%
Asia Pacific Reported Growth (YoY)(%)
-10.0%-6.0%-4.0%-1.0%1.0%3.0%-2.0%7.0%0.0%-1.0%4.0%
Asia Pacific Foreign Currency Impact(%)
5.0%0.0%0.0%1.0%-6.0%2.0%5.0%0.0%7.0%8.0%
CooperSurgical — Organic Revenue Growth (YoY)(%)4
3.0%6.0%2.0%4.0%2.0%7.0%2.0%5.0%5.0%4.0%8.0%
Constant Currency Revenue Growth (YoY)(%)
2.0%6.0%2.0%4.0%4.0%9.0%4.0%12.0%10.0%8.0%13.0%
Reported GAAP Revenue Growth (YoY)(%)
2.0%8.0%3.0%4.0%4.0%8.0%3.0%12.0%9.0%6.0%12.0%
Foreign Currency Impact(%)
0.0%-2.0%-1.0%0.0%0.0%1.0%1.0%0.0%1.0%2.0%
Acquisitions & Divestitures Impact(%)
1.0%0.0%0.0%0.0%-2.0%-2.0%-2.0%-7.0%-5.0%-4.0%
Fertility Portfolio — Organic Revenue Growth (YoY)(%)4
5.0%10.0%3.0%1.0%3.0%2.0%1.0%13.0%10.0%4.0%11.0%
Fertility Constant Currency Growth (YoY)(%)
4.0%10.0%3.0%1.0%4.0%4.0%3.0%15.0%9.0%2.0%9.0%
Fertility Reported Growth (YoY)(%)
3.0%13.0%6.0%1.0%6.0%3.0%1.0%15.0%6.0%-1.0%6.0%
Fertility Foreign Currency Impact(%)
1.0%-3.0%-3.0%0.0%-2.0%1.0%2.0%0.0%3.0%3.0%
Fertility Acquisitions & Divestitures Impact(%)
1.0%0.0%0.0%0.0%-1.0%-2.0%-2.0%-2.0%1.0%2.0%
Office & Surgical Portfolio — Organic Revenue Growth (YoY)(%)5
2.0%4.0%2.0%6.0%1.0%10.0%2.0%0.0%2.0%4.0%6.0%
Specialty & OB/GYN Medical Devices Subsegment — Organic Growth (YoY)(%)
4.0%6.0%6.0%
Office & Surgical Constant Currency Growth (YoY)(%)
2.0%4.0%1.0%6.0%3.0%13.0%4.0%11.0%11.0%12.0%16.0%
Office & Surgical Reported Growth (YoY)(%)
2.0%4.0%2.0%6.0%3.0%13.0%4.0%11.0%11.0%12.0%16.0%
Office & Surgical Foreign Currency Impact(%)
0.0%0.0%-1.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Office & Surgical Acquisitions & Divestitures Impact(%)
0.0%0.0%1.0%0.0%-2.0%-3.0%-2.0%-11.0%-9.0%-8.0%
Non-Current Customer Contract Liabilities (Multi-Year Stem Cell Storage)($M)2
209209206202199196193193191189186
Current Customer Contract Liabilities (Deferred Revenue)($M)
130128130128127128126130126122122
Revenue Recognized from Beginning-of-Year Contract Liability Balance($M)
3232.53231.931.632.531.6303131
CooperVision — Research & Development Expense($M)8
22.322.122.424.325.622.5
CooperSurgical — Research & Development Expense($M)
19.320.421.920.319.918.2
CooperVision — SG&A Expense($M)
245252238248237230
CooperSurgical — SG&A Expense($M)
132402128151137136
Corporate Unallocated SG&A Expense($M)
24.621.624.222.725.322.1
CooperVision — Depreciation Expense($M)
40.941.341.13937.135.3
CooperSurgical — Depreciation Expense($M)
6.706.506.506.705.906.10
CooperVision — Intangible Amortization Expense($M)
4.204.204.105.105.104.80
CooperSurgical — Intangible Amortization Expense($M)
42.843.543.844.944.744.8
Consolidated Organic Revenue Growth (YoY)(%)2
1.0%5.0%3.0%3.0%2.0%7.0%6.0%7.0%8.0%8.0%8.0%
Consolidated Constant Currency Revenue Growth (YoY)(%)
1.0%5.0%3.0%3.0%3.0%7.0%6.0%9.0%10.0%9.0%8.0%
Consolidated Reported Revenue Growth (YoY)(%)
1.0%8.0%6.0%5.0%6.0%6.0%4.0%10.0%8.0%7.0%9.0%
Common Shares Repurchased(M)3
4.900.201.100.700.5000000
Remaining Share Repurchase Authorization($M)
522861874966164216256256256256
Average Price Paid per Repurchased Share($)
69.1675.8482.0471.9775.60
Treasury Stock Held at Period-End(M)
27.82322.821.718.818.117.617.617.617.717.7
Non-GAAP Diluted EPS($)10
1.151.211.101.151.100.960.921.040.960.850.85
Non-GAAP Net Income($M)
222237217228220194184209192170171
Non-GAAP Operating Income($M)
281297275288276250242263256225227
Non-GAAP Operating Margin(%)
26.0%27.0%27.0%27.0%26.0%25.0%25.0%26.0%26.0%24.0%24.0%
Non-GAAP Gross Profit($M)
711736698705713682662682668634627
Non-GAAP Gross Margin(%)
67.0%68.0%68.0%66.0%67.0%68.0%69.0%67.0%67.0%67.0%67.0%
EU MDR & IVDR Medical Device Regulation Compliance Costs (Operating)($M)
2.602.604.306.404.805.305.4045.6055.20
EU MDR & IVDR Compliance Costs in Cost of Goods Sold($M)
0.600.700.701.900.700.700.600.4010.701
Acquisition & Integration-Related Charges (Operating)($M)
-1.400015.713.69.604.307.201.101.8010.5
Business Optimization & Restructuring Charges (Operating)($M)
1.101.101.9048.22.70002.904.404.206.80
Exit of Business & Product Line Rationalization Charges (Operating)($M)
001.8024.627.20002.501.100.40
Full-Year Consolidated Organic Growth Guidance — Low(%)13
2.0%3.5%4.5%4.5%4.0%5.0%6.0%6.0%8.0%7.5%7.0%
Full-Year Consolidated Organic Growth Guidance — High(%)
3.0%4.5%5.5%5.5%4.5%6.0%8.0%8.0%8.5%8.5%8.0%
Full-Year Consolidated Revenue Guidance — Low($M)
4,2294,2854,3064,2994,0764,1074,0804,0803,8923,8633,847
Full-Year Consolidated Revenue Guidance — High($M)
4,2524,3214,3464,3384,0964,1464,1584,1583,9133,9053,897
Full-Year CooperVision Organic Growth Guidance — Low(%)
1.0%3.5%4.5%4.5%4.0%6.0%6.5%6.5%9.0%8.5%8.0%
Full-Year CooperVision Organic Growth Guidance — High(%)
2.0%4.5%5.5%5.5%5.0%7.0%8.5%8.5%9.5%9.5%9.0%
Full-Year CooperVision Revenue Guidance — Low($M)
2,8282,8832,9062,9002,7342,7592,7332,7332,6062,5912,573
Full-Year CooperVision Revenue Guidance — High($M)
2,8422,9082,9322,9252,7472,7862,7862,7862,6182,6132,604
Full-Year CooperSurgical Organic Growth Guidance — Low(%)
4.0%4.0%4.0%4.0%3.0%3.5%4.0%4.0%5.5%5.0%5.0%
Full-Year CooperSurgical Organic Growth Guidance — High(%)
5.0%5.0%5.0%5.0%3.5%4.5%6.0%6.0%6.5%7.0%7.0%
Full-Year CooperSurgical Revenue Guidance — Low($M)
1,4011,4021,4001,3991,3431,3471,3471,3471,2861,2721,274
Full-Year CooperSurgical Revenue Guidance — High($M)
1,4101,4141,4131,4131,3491,3591,3721,3721,2941,2921,293
Full-Year Non-GAAP Diluted EPS Guidance — Low($)
4.514.584.584.454.084.053.943.923.643.543.50
Full-Year Non-GAAP Diluted EPS Guidance — High($)
4.554.664.664.604.124.114.024.023.673.603.58
Inventory — Finished Goods($M)3
705695672633662660628596545540520
Inventory — Raw Materials($M)
184181180193199202195188215213209
Inventory — Work-in-Process($M)
2220.924.119.92018.320.118.519.523.118.8
Allowance for Credit Losses on Trade Receivables($M)
76.169.158.751.952.152.248.143.542.839.934.7
Gross PP&E — Machinery & Automated Contact Lens Molding Equipment1
Depreciation of Property, Plant & Equipment($M)
47.647.847.645.74341.4
Finite-Lived Intangible Assets — Gross Carrying Amount($M)13
3,1653,1763,1773,1703,1903,1973,1863,1913,1373,0903,093
Finite-Lived Intangible Assets — Accumulated Amortization($M)
1,7211,6831,6361,5851,5551,5041,4481,4011,3521,3021,254
Finite-Lived Intangible Assets — Net Carrying Amount($M)
1,4451,4931,5411,5851,6351,6931,7381,7891,7851,7881,839
Gross Intangibles — Customer Relationships($M)
1,1381,1421,1431,1381,1371,1361,1261,1311,1231,1231,126
Gross Intangibles — Composite Intangible Assets($M)
1,1021,1021,1021,1021,1021,1021,1021,1021,1021,0621,062
Gross Intangibles — Patents & Technology($M)
692685684683703707707706660653653
Gross Intangibles — Trademarks($M)
199203203203203205203204204204205
Gross Intangibles — License, Distribution Rights & Other($M)
33.744.644.544.544.747.947.947.94847.747.8
Indefinite-Lived Intangible Assets (Excluding Goodwill)($M)
1.101.101.101.101.101.101.901.801.909.309.30
Amortization of Intangible Assets($M)
4747.747.95049.849.650.250.450.350.3
Estimated Intangible Amortization — Year 1 (Next Fiscal Year)($M)
174175175189189191190198192188188
Estimated Intangible Amortization — Year 2($M)
170170170174175176176190184180180
Estimated Intangible Amortization — Year 3($M)
166166166170170172171176170166166
Estimated Intangible Amortization — Year 4($M)
162162162166166167167171165161161
Committed Revolving & Term Credit Facility Capacity3
Finance Lease Liabilities — Non-Current($M)
1.601.801.701.801.9022.102.402.8033.30
Finance Lease Liabilities — Current($M)
0.600.700.600.700.90111.10111
Current Employee-Related Compensation & Benefit Liabilities($M)
175166210211181157190175157145179
FDA Premarket Approvals & Supplements (PMA — CooperVision & CooperSurgical)5
13754107581502
FDA 510(k) Clearances (CooperVision, CooperSurgical & Subsidiaries)
100010100001
FDA Medical Device Recall Events (CooperVision & CooperSurgical)
400035167023
FDA Enforcement Reports (CooperVision & CooperSurgical)
400035167023
U.S. MedTech Industry — Total FDA PMA Decisions
568616641434613597564607569575486582
U.S. MedTech Industry — Total FDA 510(k) Clearances
868889835736823882767812814793750780
FDA MAUDE Medical Device Reports — Cooper Total MDRs4
1476360453238414261476051
FDA MAUDE MDRs — Device Malfunction
993517163914211312228
FDA MAUDE MDRs — Injury
472843292828272148353843
FDA MAUDE MDRs — Death
000001000000
U.S. MedTech Industry — Total FDA MAUDE MDRs
1,137,930963,665824,539784,473760,623743,346650,998704,375705,389660,962598,054575,423
ClinicalTrials.gov — Sponsored Studies Started (CooperVision & CooperSurgical)
131211243346
Consolidated Net Sales($M)8
1,0661,0821,0241,0651,0601,0029651,0181,003943932
Gross Profit($M)
712735695651692679660678663631624
Research & Development Expense($M)
41.642.544.341.444.645.540.737.73938.939.5
Selling, General & Administrative Expense($M)
401676390419422399388391381380381
Operating Income($M)
222-31213140176185182198193162153
Interest Expense($M)
21.520.922.424.425.424.2262728.528.929.9
Net Income Attributable to Cooper Stockholders($M)
433-77.913184.698.387.710411810588.981.2
GAAP Diluted EPS($)
0-00000000
Weighted-Average Diluted Shares(M)
193195197200201201201201200
Operating Cash Flow($M)3
34218326124826196.2191268208111123
Capital Expenditures($M)
68.786.41029896.978.189.41408974.1118
Stock-Based Compensation($M)
15.915.519.215.216.220.318.816.417.617.223.9
Cash Paid for Share Repurchases($M)
33915.592.519752.740.6-0-0-0
Total Assets($M)7
12,67312,48212,42412,39512,37712,41412,22212,31512,10812,04712,033
Cash & Cash Equivalents($M)
155139125111125116101108110112135
Accounts Receivable, Net($M)
789809807829792781716717739689651
Inventories, Net($M)
912896876846881880843803779775748
Property, Plant & Equipment, Net($M)
2,1452,1322,1172,0821,9891,9291,8651,8611,7481,7091,682
Goodwill($M)
3,8763,8893,9053,8533,8623,8653,7923,8383,7773,7613,773
Other Intangible Assets, Net($M)
1,4461,4941,5421,5861,6361,6941,7391,7911,7871,7971,848
Total Stockholders' Equity($M)
8,3288,2398,3648,2398,3538,2888,1278,0837,9257,8047,695

15 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • The Cooper Companies, Inc. operates on a fiscal year ending October 31 (for example, FY2025 ended October 31, 2025; Q1 FY2026 ended January 31, 2026; Q2 FY2026 ended April 30, 2026; Q3 FY2026 ended July 31, 2026).
  • Primary operational metrics focus on: (1) CooperVision organic and constant-currency revenue growth, pediatric myopia control (MiSight 1 day) organic growth, and CooperVision regional net sales across EMEA, Americas, and Asia Pacific; (2) CooperSurgical organic growth across Fertility and Office & Surgical (including Specialty/OB-GYN Medical Devices), prepaid multi-year newborn stem cell storage contract liabilities (Cord Blood Registry), and ASU 2023-07 segment R&D, SG&A, depreciation, and amortization; and (3) monthly and quarterly share repurchases, split-adjusted Non-GAAP execution, EU MDR/IVDR regulatory compliance costs, and quarterly full-year guidance.
  • All growth rates, regional net sales, non-GAAP reconciliations, sustainability figures, and statutory UK subsidiary metrics are directly reported; no ratios, margins, sums, or growth rates are computed. The only derived cells are cumulative period splits from year-to-date cash flow and footnote tables (Q4 = full year − nine months; quarterly = year-to-date − prior year-to-date). Per-share metrics reflect the 4-for-1 stock split completed in February 2024.

Không hiện vì thiếu các kỳ gần đây (11)

  • CooperVision — Organic Growth, Myopia Control & Regional Mix (Key #1) › MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY) › MiSight 1 day Quarterly Revenue — excluded due to missing recent periods required for strict continuity
  • CooperVision — Organic Growth, Myopia Control & Regional Mix (Key #1) › MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY) › Daily Silicone Hydrogel Portfolio — Organic Growth (YoY) — excluded due to missing recent periods required for strict continuity
  • Consolidated Organic Growth, Share Repurchases, Non-GAAP Execution & Guidance (Key #3) › Common Shares Repurchased › Monthly Average Price Paid per Repurchased Share — excluded due to missing recent periods required for strict continuity
  • Manufacturing Capacity, Inventory Stages, Intangibles & Lease Commitments › Committed Revolving & Term Credit Facility Capacity › Current Litigation Settlement Reserve — excluded due to missing recent periods required for strict continuity
  • Form 10-K Year-End Global Headcount ('more than 15,000' as of October 31, 2025) — excluded because disclosed as an open-ended lower bound in Form 10-K; exact point headcounts from the Corporate Sustainability Reports (15,496 in FY2025) are included instead
  • Global Contact Lens Wearer Share ('roughly 1/3 of all wearers' / '#1 global contact lens company' in Q2 FY2026 earnings call) — excluded because disclosed qualitatively without a continuous numerical series
  • Paragard IUD Quarterly Organic Revenue Growth (%) — excluded because Q2 and Q3 FY2026 earnings calls described performance qualitatively as 'flat' without an explicit numerical digit
  • Workforce Gender & U.S. Racial/Ethnic Representation (%) — reported for 2021–2024 in prior Sustainability Reports but discontinued in the 2025 Corporate Sustainability Report
  • Global Employee Engagement Rate (84% in 2023, 90% in 2024) — excluded because the global engagement survey was not conducted in 2025
  • Scope 3 GHG Emissions (701,680 tCO2e in FY2025) — excluded because disclosed as a single-year figure in the 2025 Corporate Sustainability Report (<2 consecutive years)
  • Long-Term Cumulative Free Cash Flow Objective ('exceeding $2.2 billion for fiscal years 2026 through 2028') — excluded because stated as a multi-year open-ended lower bound

Dữ liệu cập nhật 2026-11-18.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Cooper Companies

See a number that looks wrong?